Description: Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Home Page: www.evolus.com
520 Newport Center Drive
Newport Beach,
CA
92660
United States
Phone:
949 284 4555
Officers
| Name | Title |
|---|---|
| Mr. David Moatazedi | President, CEO & Director |
| Ms. Sandra Beaver | Chief Financial Officer |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development |
| Mr. Nareg Sagherian | Head of Global Investor Relations & Corporate Communications |
| Mr. Jeffrey J. Plumer | General Counsel |
| Mr. Kurt Knab | Vice President of Sales |
| Ms. Tomoko Yamagishi-Dressler | Chief Marketing Officer |
| Ms. Jessica Novak | Senior Vice President of Human Resources |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 96.1538 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 134.283 |
| Price-to-Sales TTM: | 3.0782 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 322 |